Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Immunoglobulin Light-chain Amyloidosis 2Amyloidosis 1Amyloid Neuropathies, Familial 1

Interventions

pembrolizumab 247Nivolumab 144Cyclophosphamide 137Cisplatin 137Paclitaxel 115Carboplatin 111Gemcitabine 100Radiotherapy 86Dexamethasone 84Docetaxel 79Ipilimumab 70atezolizumab 68Doxorubicin 63Fluorouracil 60Blood Specimen Collection 60Bevacizumab 59Etoposide 55fludarabine 54Rituximab 54Oxaliplatin 52Prednisone 51Lenalidomide 51Surveys and Questionnaires 50Cetuximab 47Standard of Care 46Capecitabine 46Radiosurgery 44Magnetic Resonance Spectroscopy 44lenvatinib 43durvalumab 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene × 1 year × Clear all
NCT05184088 2026-06-02

CArdiag

Lantheus Biosciences Ltd.

Phase 3 Completed
244 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial

NCT04392960 2026-04-16

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase NA Completed
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡